While AI dominates current conversations, Techstars' David Cohen believes Quantum Computing represents a far larger future paradigm shift. He posits that a single quantum computer will eventually surpass the combined power of all AI-driven classical computers. The "killer app" for this new era will be in healthcare, enabling truly personalized medicine.
Related Insights
Contrary to the belief that it has no current utility, quantum computing is already being used commercially and generating revenue. Major companies like HSBC and AstraZeneca are leveraging quantum machines via cloud platforms (AWS, Azure) for practical applications like financial modeling and drug discovery, proving its value today.
The next evolution in personalized medicine will be interoperability between personal and clinical AIs. A patient's AI, rich with daily context, will interface with their doctor's AI, trained on clinical data, to create a shared understanding before the human consultation begins.
A "software-only singularity," where AI recursively improves itself, is unlikely. Progress is fundamentally tied to large-scale, costly physical experiments (i.e., compute). The massive spending on experimental compute over pure researcher salaries indicates that physical experimentation, not just algorithms, remains the primary driver of breakthroughs.
The tech world is fixated on trivial AI uses while monumental breakthroughs in healthcare go underappreciated. Innovations like CRISPR and GLP-1s can solve systemic problems like chronic disease and rising healthcare costs, offering far greater societal ROI and impact on longevity than current AI chatbots.
While AI's impact on business is significant, the ultimate catalyst for market euphoria will be its application in healthcare. When AI-driven drug discovery makes 'living forever' a tangible possibility, it will unlock an unprecedented level of investor optimism.
An effective AI strategy in healthcare is not limited to consumer-facing assistants. A critical focus is building tools to augment the clinicians themselves. An AI 'assistant' for doctors to surface information and guide decisions scales expertise and improves care quality from the inside out.
Nvidia CEO Jensen Huang's public stance on quantum computing shifted dramatically within months, from a 15-30 year timeline to calling it an 'inflection point' and investing billions. This rapid reversal from a key leader in parallel processing suggests a significant, non-public breakthrough or acceleration is underway in the quantum field.
Despite hype around its potential to solve famously complex problems like the "traveling salesman," experts in the field caution that the number of actual, practical problems quantum computing can currently solve is extremely small. The gap between its theoretical power and tangible business application remains vast, making its near-term commercial impact questionable.
A symbiotic relationship exists between AI and quantum computing, where AI is used to significantly speed up the optimization and calibration of quantum machines. By automating solutions to the critical 'noise' and error-rate problems, AI is shortening the development timeline for achieving stable, powerful quantum computers.
The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.